Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B3139 vs crizotinib in ALK-positive advanced NSCLC (CTR20191289)
CTR20191289Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of envonalkib in non-small cell lung cancer (NSCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Sep 2019; status: completed.
02
Drugs
envonalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20191289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191289.